Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been given an average recommendation of "Buy" by the ten ratings firms that are presently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $46.43.

Several brokerages recently weighed in on DNTH. Raymond James increased their price objective on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the company an "outperform" rating in a report on Friday, November 8th. Wedbush lowered their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a report on Friday, August 9th. Oppenheimer boosted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, November 11th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th.

Institutional Trading of Dianthus Therapeutics

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company's stock valued at $16,135,000 after buying an additional 384,182 shares during the period. Bank of New York Mellon Corp grew its position in Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock valued at $2,095,000 after purchasing an additional 72,509 shares during the period. SG Americas Securities LLC increased its stake in Dianthus Therapeutics by 104.0% during the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company's stock valued at $242,000 after purchasing an additional 4,506 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Dianthus Therapeutics by 281.9% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company's stock valued at $1,022,000 after buying an additional 29,159 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Dianthus Therapeutics by 38.6% during the second quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock worth $788,000 after acquiring an additional 8,473 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Price Performance

Shares of DNTH traded up $0.88 on Monday, hitting $24.87. The company's stock had a trading volume of 66,482 shares, compared to its average volume of 205,500. The company has a market capitalization of $736.15 million, a PE ratio of -9.60 and a beta of 1.84. The company has a 50 day moving average price of $26.66 and a 200 day moving average price of $26.54. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. On average, equities analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.